AR and neoplasm: Patients with AR + /FOXA1 + , AR + /FOXA1- and AR- tumours showed 3-year RFS rates of 79.8%, 79.1% and 86.9% respectively and 5-year RFS rates of 66.8%, 79.1% and 79.7% (Fig. 1a).